MX347164B - Anticuerpos anti-il-36r. - Google Patents

Anticuerpos anti-il-36r.

Info

Publication number
MX347164B
MX347164B MX2014005759A MX2014005759A MX347164B MX 347164 B MX347164 B MX 347164B MX 2014005759 A MX2014005759 A MX 2014005759A MX 2014005759 A MX2014005759 A MX 2014005759A MX 347164 B MX347164 B MX 347164B
Authority
MX
Mexico
Prior art keywords
antibodies
therapeutic
compositions
same
relates
Prior art date
Application number
MX2014005759A
Other languages
English (en)
Other versions
MX2014005759A (es
Inventor
Canada Keith
Brown Su-Ellen
Chlewicki Lukasz
Howell Michael
Robert Woska Joseph Jr
Mennerich Detlev
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215803&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347164(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2014005759A publication Critical patent/MX2014005759A/es
Publication of MX347164B publication Critical patent/MX347164B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Abstract

La presente invención se refiere a anticuerpos anti-IL-36R y composiciones farmacéuticas que los contienen.
MX2014005759A 2011-11-16 2012-11-14 Anticuerpos anti-il-36r. MX347164B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161560554P 2011-11-16 2011-11-16
US201261644111P 2012-05-08 2012-05-08
US201261713713P 2012-10-15 2012-10-15
PCT/US2012/064933 WO2013074569A1 (en) 2011-11-16 2012-11-14 Anti il-36r antibodies

Publications (2)

Publication Number Publication Date
MX2014005759A MX2014005759A (es) 2014-09-08
MX347164B true MX347164B (es) 2017-04-18

Family

ID=47215803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005759A MX347164B (es) 2011-11-16 2012-11-14 Anticuerpos anti-il-36r.

Country Status (38)

Country Link
US (3) US9023995B2 (es)
EP (2) EP3536710A1 (es)
JP (3) JP6289375B2 (es)
KR (3) KR20200110476A (es)
CN (3) CN112812183A (es)
AP (1) AP2014007571A0 (es)
AR (1) AR089178A1 (es)
AU (1) AU2012339734B2 (es)
BR (1) BR112014011594B1 (es)
CA (1) CA2852994C (es)
CL (1) CL2014001123A1 (es)
CO (1) CO7020871A2 (es)
CY (1) CY1122278T1 (es)
DK (1) DK2780373T3 (es)
EA (1) EA031948B1 (es)
EC (1) ECSP14004976A (es)
ES (1) ES2755732T3 (es)
FI (1) FIC20230020I1 (es)
FR (1) FR23C1023I2 (es)
HR (1) HRP20191835T1 (es)
HU (2) HUE047437T2 (es)
IL (2) IL232100B (es)
LT (2) LT2780373T (es)
MX (1) MX347164B (es)
MY (1) MY195289A (es)
NL (1) NL301233I2 (es)
PE (1) PE20142041A1 (es)
PH (1) PH12014501108B1 (es)
PL (1) PL2780373T3 (es)
PT (1) PT2780373T (es)
RS (1) RS59248B1 (es)
SG (1) SG11201402283PA (es)
SI (1) SI2780373T1 (es)
TW (1) TWI573804B (es)
UA (1) UA115540C2 (es)
UY (1) UY34456A (es)
WO (1) WO2013074569A1 (es)
ZA (1) ZA201402491B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858350A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
AU2012339734B2 (en) 2011-11-16 2017-02-16 Boehringer Ingelheim International Gmbh Anti IL-36R antibodies
SI2817338T1 (sl) 2012-02-24 2017-11-30 Abbvie Stemcentrx Llc Modulatorji DLL3 in postopki uporabe
KR20220126813A (ko) * 2014-03-14 2022-09-16 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
BR112017022086A2 (pt) * 2015-04-15 2018-07-03 Anaptysbio Inc anticorpos dirigidos contra o receptor de interleucina 36 (il-36r)
WO2016201282A2 (en) * 2015-06-12 2016-12-15 Ludwig Institute For Cancer Research Ltd TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
WO2018085469A2 (en) 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
MA47206A (fr) 2017-01-09 2019-11-13 Tesaro Inc Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
EP3601350A1 (en) * 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Anti il-36r antibodies combination therapy
EP3737366A4 (en) * 2018-01-08 2022-07-27 ChemoCentryx, Inc. METHOD OF TREATMENT OF GENERALIZED PUSTULOUS PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2
MX2020009544A (es) * 2018-03-14 2020-10-05 Boehringer Ingelheim Int Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada.
KR20200131303A (ko) * 2018-03-14 2020-11-23 베링거 인겔하임 인터내셔날 게엠베하 염증성 장질환의 치료를 위한 항-il-36r 항체의 용도
JP2021530970A (ja) * 2018-07-16 2021-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Ｄｉｔｒａの非ヒト動物モデルおよびその使用
WO2020018503A2 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
CN112638946A (zh) 2018-08-16 2021-04-09 坎塔吉亚有限责任公司 抗il1rap抗体组合物
CN112839957A (zh) * 2018-09-28 2021-05-25 协和麒麟株式会社 Il-36抗体及其用途
KR20210107721A (ko) 2018-12-21 2021-09-01 23앤드미 인코포레이티드 항-il-36 항체 및 이의 사용 방법
BR112021010789A2 (pt) 2018-12-27 2021-08-31 Boehringer Ingelheim International Gmbh Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
BR112021016198A2 (pt) * 2019-03-08 2021-11-03 Boehringer Ingelheim Int Gmbh Formulações de anticorpo anti-il-36r
US20220162326A1 (en) * 2019-05-13 2022-05-26 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
WO2021112196A1 (ja) * 2019-12-05 2021-06-10 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
TW202208433A (zh) 2020-05-19 2022-03-01 德商百靈佳殷格翰國際股份有限公司 用於治療異位性皮膚炎之抗ｉｌ－３６ｒ抗體
WO2022015920A1 (en) 2020-07-17 2022-01-20 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN116406295A (zh) 2020-07-30 2023-07-07 安奈普泰斯生物有限公司 针对鱼鳞病的抗白介素36受体（il-36r）疗法
CA3192882A1 (en) 2020-09-30 2022-04-07 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
EP4289863A1 (en) * 2020-12-17 2023-12-13 Shanghai Huaota Biopharmaceutical Co., Ltd. Bispecific antibody targeting il-17a and il-36r and application thereof
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
TW202302644A (zh) 2021-03-04 2023-01-16 德商百靈佳殷格翰國際股份有限公司 治療gpp之方法
WO2022192531A2 (en) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
TW202309087A (zh) * 2021-05-03 2023-03-01 德商百靈佳殷格翰國際股份有限公司 製備spesolimab之方法
EP4357361A1 (en) * 2021-06-18 2024-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-il-36r antibody and use thereof
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
WO2023019232A1 (en) 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition
WO2023052222A2 (en) 2021-09-28 2023-04-06 Boehringer Ingelheim International Gmbh System and method for assessing severity of neutrophilic dermatoses with visible skin manifestation
TW202334200A (zh) * 2021-10-28 2023-09-01 美商艾伯維有限公司 抗澱粉樣蛋白β抗體及其使用方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ATE161192T1 (de) 1992-08-21 1998-01-15 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
ES2274574T3 (es) 1997-08-01 2007-05-16 Schering Corporation Proteinas de membrana celular de mamifero; reactivos relacionados.
LT2857516T (lt) * 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
EP1627927A3 (en) * 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
AU2003282667A1 (en) * 2002-10-03 2004-04-23 Large Scale Biology Corporation Multimeric protein engineering
CN101370525B (zh) * 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2662549C (en) 2006-09-08 2014-10-28 Amgen Inc. Il-1 family variants
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗ｍｄｌ−１抗体
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
AU2009285585A1 (en) 2008-08-28 2010-03-04 Wyeth Llc Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases
AU2012339734B2 (en) 2011-11-16 2017-02-16 Boehringer Ingelheim International Gmbh Anti IL-36R antibodies
BR112017022086A2 (pt) 2015-04-15 2018-07-03 Anaptysbio Inc anticorpos dirigidos contra o receptor de interleucina 36 (il-36r)

Also Published As

Publication number Publication date
MY195289A (en) 2023-01-12
AR089178A1 (es) 2014-08-06
JP2015500633A (ja) 2015-01-08
IL232100A0 (en) 2014-05-28
US20130236471A1 (en) 2013-09-12
CA2852994C (en) 2023-02-14
TW201333037A (zh) 2013-08-16
EP3536710A1 (en) 2019-09-11
CY1122278T1 (el) 2020-11-25
JP6289375B2 (ja) 2018-03-07
NL301233I2 (nl) 2023-09-13
UA115540C2 (uk) 2017-11-27
DK2780373T3 (da) 2019-11-04
HUE047437T2 (hu) 2020-04-28
PE20142041A1 (es) 2014-12-18
LT2780373T (lt) 2019-09-25
US20170298135A9 (en) 2017-10-19
FR23C1023I2 (fr) 2024-03-29
MX2014005759A (es) 2014-09-08
ZA201402491B (en) 2021-09-29
AU2012339734A1 (en) 2014-04-24
ES2755732T3 (es) 2020-04-23
BR112014011594A2 (pt) 2017-07-04
EP2780373A1 (en) 2014-09-24
CN112812183A (zh) 2021-05-18
CN104080808A (zh) 2014-10-01
IL272035A (en) 2020-02-27
EA031948B1 (ru) 2019-03-29
US10550189B2 (en) 2020-02-04
AP2014007571A0 (en) 2014-04-30
KR20200110476A (ko) 2020-09-23
IL232100B (en) 2020-04-30
RS59248B1 (sr) 2019-10-31
NL301233I1 (es) 2023-06-07
CO7020871A2 (es) 2014-08-11
SI2780373T1 (sl) 2019-12-31
SG11201402283PA (en) 2014-06-27
JP2020156506A (ja) 2020-10-01
AU2012339734B2 (en) 2017-02-16
ECSP14004976A (es) 2015-11-30
BR112014011594B1 (pt) 2021-11-09
CA2852994A1 (en) 2013-05-23
KR102038310B1 (ko) 2019-11-01
PT2780373T (pt) 2019-11-27
LTPA2023518I1 (es) 2023-06-12
CN107007833B (zh) 2020-12-11
TWI573804B (zh) 2017-03-11
PH12014501108A1 (en) 2014-08-04
HRP20191835T1 (hr) 2019-12-27
NZ623425A (en) 2015-12-24
CL2014001123A1 (es) 2015-01-23
HUS2300021I1 (hu) 2023-07-28
CN107007833A (zh) 2017-08-04
PL2780373T3 (pl) 2020-03-31
US20150203584A1 (en) 2015-07-23
PH12014501108B1 (en) 2014-08-04
EA201400579A1 (ru) 2014-10-30
WO2013074569A1 (en) 2013-05-23
JP2018093885A (ja) 2018-06-21
CN104080808B (zh) 2016-11-16
US9023995B2 (en) 2015-05-05
EP2780373B1 (en) 2019-08-21
FR23C1023I1 (fr) 2023-07-21
JP6719490B2 (ja) 2020-07-08
UY34456A (es) 2013-05-31
FIC20230020I1 (fi) 2023-06-01
KR20190122877A (ko) 2019-10-30
KR102159109B1 (ko) 2020-09-23
US20200231684A1 (en) 2020-07-23
KR20140101738A (ko) 2014-08-20

Similar Documents

Publication Publication Date Title
MX347164B (es) Anticuerpos anti-il-36r.
PH12014502406A1 (en) Anti-il-23p19 antibodies
MX343858B (es) Anticuerpos anti-il-23.
HK1201274A1 (en) 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof 33- 19-
TN2012000462A1 (en) Anti-cd40 antibodies
TN2014000134A1 (en) Therapeutic peptides
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
EP2714081A4 (en) METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
IN2014DN08481A (es)
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
WO2013093627A3 (en) In silico affinity maturation
TN2014000207A1 (en) Anti il-36r antibodies
AR123070A2 (es) Anticuerpos anti-il-23
TN2013000186A1 (en) Anti-il-23 antibodies
NZ626296A (en) Compositions and methods for antibodies targeting factor p
TN2013000265A1 (en) Anti-cd38 antibodies

Legal Events

Date Code Title Description
FG Grant or registration